FDA Issues Warning Letter to Novo Nordisk Over GLP-1 Reporting Violations

The Food and Drug Administration has issued a warning letter to Novo Nordisk, citing violations of regulations concerning the reporting of adverse events associated with its GLP-1 receptor agonist medications, semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda). The findings stem from an inspection conducted between January and February of 2025, and raise questions about the thoroughness of the company’s pharmacovigilance processes.

The FDA’s concerns center on instances where Novo Nordisk failed to properly document, investigate, or report adverse events, including cases of serious outcomes like death and suicidal ideation. While the agency acknowledged the company’s subsequent corrective actions, the letter indicates these efforts were deemed insufficient to guarantee future compliance. This development arrives as GLP-1 medications continue to gain prominence, not only for diabetes management but also for weight loss, leading to increased scrutiny of their safety profiles.

Specific Violations Highlighted by the FDA

The warning letter details several specific instances of non-compliance. One case involved a patient fatality where a valid patient identifier wasn’t included in the initial report within the required timeframe, though it was available in source documents. Another cited a delay in medical review – exceeding the 10-day limit – for a patient reporting suicidal thoughts while taking semaglutide. The FDA also flagged instances where cases were closed without proper investigation or reporting, including a patient death and a report of a stroke potentially linked to liraglutide. The agency stated Novo Nordisk rejected the stroke case, claiming it wasn’t related to the drug, despite it being considered a “serious and unexpected” event requiring reporting.

These violations aren’t simply procedural; they underscore the importance of robust adverse event reporting systems. Pharmacovigilance, the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem, relies on accurate and timely reporting to identify potential safety signals and inform regulatory decisions. A delay or failure in reporting can hinder the ability to detect rare but serious side effects.

Novo Nordisk’s Response and Corrective Actions

Novo Nordisk acknowledged receipt of the warning letter and stated it has been working to address the FDA’s concerns since the initial inspection in 2025. The company emphasized that the letter pertains to regulatory compliance and doesn’t question the quality or safety of its medications. According to a press release, Novo Nordisk has contracted with a consultant to review its pharmacovigilance processes, deviation systems, and corrective and preventive action systems. They’ve also undertaken a review of closed pharmacovigilance-related deviations dating back to June 2017.

Anna Windle, head of clinical development, medical and regulatory affairs at Novo Nordisk US, stated the company intends to address the FDA’s requests “expeditiously and holistically.” Although, the FDA’s letter indicates that the initial corrective actions were not detailed enough to assure the agency that similar violations won’t occur in the future. Novo Nordisk has 15 business days from receipt of the letter to outline a plan to prevent future violations, with potential regulatory action looming if further issues arise.

GLP-1s and the Expanding Landscape of Adverse Event Monitoring

GLP-1 receptor agonists have become increasingly popular for both type 2 diabetes and weight management. Medications like semaglutide and liraglutide work by mimicking the effects of the naturally occurring GLP-1 hormone, which helps regulate blood sugar and appetite. The surge in demand, particularly for off-label weight loss use, has led to increased attention on potential side effects.

Earlier this year, the FDA investigated reports of suicidal ideation associated with GLP-1s, ultimately requesting that manufacturers remove references to this risk from drug labels following an investigation. This investigation highlights the ongoing require for vigilant monitoring of these medications, even as their benefits become more widely recognized.

What Does This Mean for Patients?

It’s important to emphasize that the FDA’s warning letter does not indicate a problem with the safety or efficacy of Novo Nordisk’s medications themselves. Rather, it focuses on the company’s processes for reporting and investigating adverse events. Patients currently taking semaglutide or liraglutide should continue their prescribed treatment plan and discuss any concerns with their healthcare provider.

The FDA’s actions serve as a reminder of the importance of reporting any suspected side effects to a healthcare professional. Patients can also report adverse events directly to the FDA through its MedWatch program: https://www.fda.gov/safety/medwatch.

The Ongoing Process of Drug Safety Surveillance

The FDA’s response to these findings exemplifies the ongoing process of drug safety surveillance. After a medication is approved and marketed, the FDA continues to monitor its safety through various mechanisms, including adverse event reporting, inspections of manufacturing facilities, and post-market studies. When potential safety concerns arise, the agency can issue warning letters, require label changes, or even recall a medication from the market.

The agency’s pharmacovigilance program relies heavily on reports submitted by healthcare professionals and patients. These reports are analyzed to identify potential safety signals, which are then investigated further. The FDA also collaborates with other regulatory agencies around the world to share information and coordinate safety efforts.

Novo Nordisk is expected to submit a detailed plan to the FDA outlining its corrective actions within the next two weeks. The agency will then review the plan to determine if it adequately addresses the concerns raised in the warning letter. The outcome of this review will determine whether further regulatory action is necessary.

For more information on GLP-1 receptor agonists and their potential side effects, patients and healthcare professionals can consult resources from the FDA and the Centers for Disease Control and Prevention.